Ioflupane

Summary

Ioflupane (CHEMBL1945778) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 431.3 Da · C18H23FINO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1945778
Name	Ioflupane
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10048368
Molecular formula	C18H23FINO2
Molecular weight	431.3
InChIKey	HXWLAJVUJSVENX-HZMVEIRTSA-N

SMILES: COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)I

IUPAC name: methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate

Also known as: .beta.-cit-fp, Ioflupane, J731.794H, NMA-78, RTI-313, IOFLUPANE

Parent form; salt/anhydrous children: CHEMBL3989517

Patent coverage: 87 distinct patent families (167 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A3	7.55	Ki	28.18	nM	CHEMBL_ACT_8025685

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00940914	PHASE2	COMPLETED	Dopaminergic Loss and Pain in Parkinson’s Disease
NCT03185182	PHASE2	TERMINATED	Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
NCT03675282	PHASE1/PHASE2	COMPLETED	Quantitative Mapping of Substantia Nigra Iron in Parkinson’s Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
NCT02138682	Not specified	UNKNOWN	Validation of DaTscan for Detection of Parkinson Disease Related Disorders

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).